Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mouskito is a line of over-the-counter (OTC) insect repellent products developed and marketed by the Belgian healthcare company Qualiphar. The product range is designed to provide protection against a variety of biting insects, including mosquitoes, ticks, and flies, which are vectors for diseases such as malaria, dengue fever, Zika virus, and Lyme disease. The Mouskito portfolio includes several formulations tailored for different needs: Mouskito Tropical (containing 50% DEET), Mouskito Family and Junior (utilizing Icaridin/Picaridin), and Mouskito Natural (based on Citriodiol/Eucalyptus citriodora oil). These active ingredients function by disrupting the insect's olfactory and gustatory receptors, effectively masking human attractants or acting as a deterrent to prevent landing and biting. The products are available in various topical formats, including sprays, lotions, and sticks, and are approved for use in both temperate and tropical environments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mouskito.